Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Laurus Labs

Ahead of Market: 10 things that will decide stock market action on Tuesday

Indian markets snapped a five-session losing streak as easing Iran-US tensions, lower crude prices and upbeat earnings lifted sentiment. Sensex climbed 776 points and Nifty reclaimed 23,996, with analysts eyeing 24,250–24,300 if the index sustains above the 24,000 mark.

The Economic Times

Laurus Labs shares rally over 4% as Q1FY27 profit jumps 126% on strong CDMO growth

Laurus Labs reported a strong June-quarter performance, with net profit more than doubling and revenue rising 29% year-on-year, driven by robust growth in its CDMO business and affordable medicines portfolio. The company also reported margin expansion, reaffirmed its capex plans, and continued to attract higher institutional interest, boosting investor sentiment.

The Economic Times

Q1 Results today: SBI Life, Tata Consumer, Hindustan Zinc among 86 companies to announce earnings

A total of 86 companies are slated to announce their Q1 FY27 earnings today, with key names including Tata Consumer Products, SBI Life Insurance, Hindustan Zinc, Shriram Finance, ACC, Bank of Baroda, Bank of India, SAIL, SBI Cards, Laurus Labs and Lodha Developers.

The Economic Times

From analysis to the latest developments in health,
read the most diverse news in one place.

MSCI India rejig: Eternal likely to see highest inflows at $648 mn; Lenskart, Groww among Nuvama’s expected inclusions

MSCI’s August India Standard Index review could trigger major passive inflows, with Eternal expected to attract the highest at $648 million, according to Nuvama. The brokerage sees Laurus Labs, Adani Energy Solutions, Lenskart and Groww among likely inclusions, while Balkrishna Industries, SBI Cards and Astral face potential exclusions.

The Economic Times

MSCI India rejig: Why Adani Green, Groww and Laurus Labs are on investors’ radar

Adani Green, Groww and Laurus Labs have emerged as key stocks to watch ahead of MSCI’s August 2026 index review. JM Financial expects up to 12 inclusions and three exclusions, potentially triggering $2.3 billion in passive inflows, with index-linked buying likely to drive liquidity, institutional ownership and near-term stock movements.

The Economic Times

Laurus Labs, Biocon, Ather Energy, Lenskart among probable MSCI India Standard Index inclusion candidates, says JM Financial

JM Financial anticipates significant shifts in the MSCI India Standard Index. Laurus Labs and Biocon are flagged as high-probability additions from the Small Cap Index, while Ather Energy and SAIL are medium-probability candidates. SBI Card faces a high probability of exclusion. These potential changes could lead to substantial passive fund…

The Economic Times

Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplash

Indian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic demand and positive global healthcare trends. Analysts see long-term growth potential from aging populations and innovation. Emerging opportunities from supply chain diversification away from China also present a positive outlook for…

The Economic Times

Read news from The Economist, FT, and more,
with one subscription

Market Trading Guide: NMDC among two stock recommendations for Tuesday

Indian benchmark indices extended losses for a fourth straight session as FII selling and geopolitical concerns hurt sentiment. Amid the weakness, analysts recommend NMDC and Laurus Labs, citing bullish chart patterns, strong momentum, breakout formations and favorable technical indicators for further upside.

The Economic Times

Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?

Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business improvements, better margins, and strong earnings, the pharma major's market cap surged. Analysts see further upside but advise caution with stop losses due to the steep rise.

The Economic Times

Laurus Labs, IIT-Kanpur to collaborate for novel gene therapy

The drug manufacturer will also fund the clinical trials and launch the products in India and emerging markets. Additionally, it will establish a GMP (good manufacturing practice) facility at the Techno Park facility of IIT-K, Laurus said on Monday.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.